Neuromodulation of long-term sequelae of ischemic acute kidney injury

Project Summary Acute kidney injury (AKI) is recognized as a major risk for progressive chronic kidney disease (CKD). However, the mechanism by which AKI leads to fibrogenesis and ultimately to end-stage renal disease (ESRD)2 is not well defined, Due to limited knowledge of the primary signals that drive fibrogenesis, effective therapy for CKD is a major unmet medical

need. Our data indicate the novel paradigm that renal denervation can prevent renal fibrosis and inflammation in three

renal fibrogenesis models: 5/6 nephrectomy (5/6Nx), unilateral ureteral obstruction (UUO) and ischemic renal injury (IRI).

Our data indicate that the renal nerve-derived factor, norepinephrine (NE), signaling via α2-adrenergic receptor (α2-AR)

plays a key role in initiating fibrogenesis and inflammation and its inhibition pre-or post-injury can reduce fibrosis by about

70% in these CKD models. This finding is striking, as most experimental strategies targeting a single molecule or a pathway

rarely achieve a reduction of fibrosis of more than 50%. Our overall goal of this study is to delineate the mechanisms by

which NE signaling via α2-AR induces fibrosis and determine the therapeutic potential of inhibition of the α2-AR subtype

or its downstream signaling pathways in preventing renal fibrogenesis and inflammation in the IRI model. Our preliminary

studies indicate that NE signaling via α2-AR induces the expression of angiotensinogen (AGT) in renal proximal tubular cell (RPTC) via activation of cAMP-response element-binding protein (CREB). Further, simultaneous inhibition of α2AR

subtypes A and C additively protected from inflammation and fibrosis, suggesting activation of subtype specific signaling pathways, parallel to CREB-AGT axis, that may promote interstitial fibrosis and CKD. Based on these data, our central

hypothesis is that NE activates α2AR-subtypes specific-signaling pathways to induce interstitial fibrosis and their inhibition

can prevent long term sequelae of IRI. Further, α2AR activation regulates parallel pathways including, fibroblast activation

and Mφ infiltration, activation and Mφ phenotypic switching, and activates Renin-Angiotensin II Signaling (RAS) signaling

pathways to promote fibrogenesis. In specific aim 1, using genetic and pharmacological approaches, we will delineate the functional and mechanistic role of the three α2-AR subtypes (A, B and C), and the effect of their inhibition on renal

fibrogenesis in the IRI-model. Using transcriptomic profile, we will identify overlapping versus specific pathways between

the α2AR subtypes and identify the signaling molecules that provides added protection after combinatorial inhibition. In

specific aim 2, we will dissect out the distinct role of of α2-AR subtype(s) cell-specific role (PTC vs. Mφ vs fibroblasts) in

cytokine secretion in fibroblast differentiation, Mφ behavior or Mφ switching and tubular injury. In specific aim 3, we will identify the α2-AR subtype/s that activates CREB and AGT signaling and determine whether inhibition of AGT prevents inflammation and fibrosis in the IRI model. The studies have high significance as they will define α2-AR as a primary

signaling molecule that regulates several of the key pathogenic molecules and processes implicated in the renal interstitial

fibrogenesis including macrophage and fibroblast activation and RAS signaling. In this regard, our studies have immediate

clinical translational potential, because α2AR inhibitors are already in clinical use in other conditions and could be adapted

rapidly to prevent the progression of fibrosis in CKD and plausibly in other organs including the liver, lung and heart.